Filings

6 documents · 36 matches

1. CADL Candel Therapeutics, Inc. 10-Q 2026-08-13

   Item 1A. Risk Factors.

   material weaknesses may have been identified. If future material weaknesses are identified in our internal control over financial reporting, or if we otherwise
   5 matches in this document Show context Copy citation

2. CADL Candel Therapeutics, Inc. 10-Q 2026-05-14

   Item 1A. Risk Factors.

   material weaknesses may have been identified. If future material weaknesses are identified in our internal control over financial reporting, or if we otherwise
   6 matches in this document Show context Copy citation

3. CADL Candel Therapeutics, Inc. 10-K 2026-03-12

   Item 1A. Risk Factors.

   material weaknesses may have been identified. If future material weaknesses are identified in our internal control over financial reporting, or if we otherwise
   7 matches in this document Show context Copy citation

4. CADL Candel Therapeutics, Inc. 10-Q 2025-11-13

   Item 1A. Risk Factors.

   material weaknesses may have been identified. If future material weaknesses are identified in our internal control over financial reporting, or if we otherwise
   6 matches in this document Show context Copy citation

5. CADL Candel Therapeutics, Inc. 10-Q 2025-08-14

   Item 1A. Risk Factors.

   material weaknesses may have been identified. If future material weaknesses are identified in our internal control over financial reporting, or if we otherwise
   6 matches in this document Show context Copy citation

6. CADL Candel Therapeutics, Inc. 10-Q 2025-05-13

   Item 1A. Risk Factors.

   with the provisions of the SOX Act, one or more material weaknesses may have been identified. If future material weaknesses are
   6 matches in this document Show context Copy citation